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The asymmetric bioreduction of activated C]C-bonds catalyzed by a single ﬂavoprotein was achieved via
direct hydrogen transfer from a sacriﬁcial 2-enone or 1,4-dione as hydrogen donor without requirement
of a nicotinamide cofactor. Due to its simplicity, this system has clear advantages over conventional FAD-
recycling systems.
 2009 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Disproportionation reactions generally furnish a 1:1 mixture of
products and are often plagued by unfavorable equilibria, hence
they are commonly considered as inefﬁcient and are rarely used in
organic synthesis.1 In biology, the disproportionation of sulfur
yielding hydrogen sulﬁde and sulfate and of hydrogen peroxide
furnishing O2 and H2O represent the most dominant dispropor-
tionation processes in Nature.2 The disproportionation of cyclohex-
2-enone, forming equimolar amounts of cyclohexanone and phenol
has been described for several ﬂavoproteins from the old yellow
enzyme (OYE) family, such as OYE isoenzymes 1–3 and estrogen-
binding protein.3 In the context of these studies, this phenomenon
has been considered either as a minor side reaction demonstrating
the catalytic promiscuity4 of OYEs or as ‘aromatase’ activity of
enoate reductases catalyzing the formation of the phenolic A-ring
in steroids, such as 17b-estradiol, from the corresponding enone-
precursor 19-nortestosterone.3 Overall, this reaction constitutes
a ﬂavin-dependent hydrogen transfer, during which an equivalent
of [2H] is formally transferred from a cyclohex-2-enone (being
oxidized) onto another one (being reduced). The oxidized product
constitutes a conjugated dienone, which spontaneously tautomer-
ises to form phenol, thereby providing a large driving force of ca.xþ32 316 380 9840.
Y-NC-ND license. 30 kcal/M for the disproportionation reaction. During this hy-
drogen-transfer reaction, the ﬂavin-cofactor is recycled internally
and no external nicotinamide cofactor is required for the reductive
half-reaction.5 In nicotinamide-dependent systems, C]C-bonds
are reduced at the expense of an external hydride donor,6 such as
formate, glucose, glucose-6-phosphate or phosphite, which re-
quires a second dehydrogenase enzyme, such as FDH, GDH,
G6PDH7 or phosphite-DH,8 respectively. This technology is gener-
ally denoted as ‘coupled-enzyme-approach’, which depends on the
concurrent operation of two independent redox enzymes for sub-
strate reduction and co-substrate-oxidation, respectively.9 Aiming
to reduce the complexity of these redox systems,10 considerable
efforts have recently been devoted to the development of nicotin-
amide-independent electrochemical and light-driven recycling
systems for reduced ﬂavins, which take advantage of the direct
transfer of a hydride (or electrons, respectively) from a donor onto
the ﬂavin.11 In this context, the nicotinamide-independent dispro-
portionation of enones is of appealing simplicity, since it requires
only a single ﬂavoprotein and represents a ‘coupled-substrate-
approach’.122. Results and discussion
In an initial screening, a set of cloned and overexpressed enoate
reductases were tested for their catalytic activity in the dispro-
portionation of cyclohex-2-enone (Scheme 1). To our delight, the
desired disproportionation activity was observed in a variety of
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teins have been reported to reduce cyclohex-2-enone to cyclo-
hexanone at the expense of NAD(P)H,13 the corresponding
disproportionation activity was exceedingly low in 12-oxophyto-
dienoic acid reductase (OPR) isoenzymes 1 & 3 and in N-ethyl-
maleimide-, morphinone-, and pentaerythritol tetranitrate
reductase. Likewise, cyclohexenone reductase from Zymomonas
mobilis showed only modest activity, whereas the OYE-homolog
YqjM14 and OYE isoenzymes15 1 and 2 from yeast were highly ac-
tive. Surprisingly, OYE isoenzyme 3 was almost inactive. The di-
vergent behavior of OYE isoenzymes is reﬂected by their structural
relationship: Whereas both highly active isoenzymes 1 and 2 show
an amino acid sequence identity of 92%, isoenzyme 3 is a more
distant relative (sequence identity 80%). The disproportionation
activity of estrogen-binding protein (EBP1)3 could be nicely
reproduced using EBP1 cloned into Escherichia coli. By taking the
strongest disproportionation activities as a lead, further experi-
ments were performed using YqjM, OYE1, and OYE2.+
OHO
Enoate Reductase
O
2 NAD(P)H-free Tris-Buffer 
pH 7.5, 30 °C
Enzyme a Conv. [%] 
OPR1 <1
OPR3 <1
NEM-Reductase <1
MOR-Reductase <1 
PETN-Reductase 0 
Zymomonas NCR-Reductase 7 
YqjM 85
OYE1 92
OYE2 75
OYE3 7 
EBP1 45
Scheme 1. Disproportionation of cyclohex-2-ene catalyzed byenoate reductases.aOPR1,
OPR3¼oxophytodienoate reductase isoenzymes 1 and 3, respectively, from tomato;16
NEM-reductase¼N-ethylmaleimide reductase;18 MOR-reductase¼morphinone re-
ductase;17 PETN-reductase¼pentaerythritol tetranitrate reductase;18 Z. mobilis NCR re-
ductase¼nicotinamide-dependent cyclohexenone reductase;19 YqjM¼OYE-homolog
from Bacillus subtilis;14 OYE1–3¼Old Yellow Enzyme isoenzymes from yeasts;15
EBP1¼estrogen-bindingprotein,3 employed as cell-free extract of E. coli expressing EBP1.In order to convert the scrambling-like hydrogen-transfer re-
action between two identical cyclohexenone molecules into a useful
directed redox process, a pair of suitable enone substrate/co-sub-
stratedone only being reduced, the other only being oxidizeddhave
to be coupled. During our previous studies on NAD(P)H-dependent
enone reduction, we observed that a-substituted cyclic enones were
quickly reduced, whereas an alkyl-substituent in the b-positionO O
[2H]
+
1 2
pH 7.5, 30 °C
NAD(P)H-free Tris-Buffer 
Enoate Reductase
Enzyme 1a 2
c [%] e.e. [%] c 
OYE1 27 [85 ( R)]
OYE2 16 [80 ( R)]
YqjM 48 [91 ( R)]
2
1
6
Scheme 2. Asymmetric hydrogen transfer between a- (1) and b-severely impeded the reaction rate.10,15 Hence, we envisaged that an
a-substituted enone might act as H-acceptor, while a b-substituted
analog would serve as H-donor.
In order to test the viability of this concept, an equimolar
amount of a- (1) and b-methylcyclohex-2-enone (2) were subjected
to OYE1, OYE2, and YqjM in a nicotinamide-free buffer system
(Scheme 2). The results of these experiments provided a clear
proof-of-concept: Depending on the enzyme, the desired reduced
a-methyl derivative 1a was formed in up to 48% conversion, while
the oxidized b-methyl analog 2b was detected in approximately
equimolar amounts.20 In contrast, only trace amounts of the cor-
responding cross-hydrogen-transfer products 1b and 2a, which
would arise from undesired oxidation of 1 and reduction of 2 were
found, indicating that the directed hydrogen transfer indeed
worked as envisaged.
Investigation of the optical purity and absolute conﬁguration of
1a revealed that the product was formed in the same highly se-
lective fashion as in the classic reduction-mode using NAD(P)H-
recycling, ensuring that the chiral induction process of the enzymes
remained unchanged.10b,15
In order to test the applicability of this nicotinamide-free C]C-
bond reduction system, we subjected two activated alkenes (3, 4),
which are known to be readily reduced by enoate reductases in
presence of NAD(P)H,10,15 to the hydrogen-transfer protocol in
presence of equimolar amounts of b-methylcyclohex-2-enone (2)
as hydrogen donor (Scheme 3). Whereas OYE1 and OYE2 showed
only modest conversion, YqjM furnished the corresponding re-
duction products 3a and 4a in up to 22% conversion together with
a stoichiometric amount of 3-methylphenol 2b. Within experi-
mental errors, the enantiomeric excess of (R)-conﬁgurated prod-
ucts 3a and 4a was identical to that of the nicotinamide-driven
process, indicating that the enzymatic chiral induction remained
intact.10,15
Since the use of equimolar amounts of 3-methylcyclohex-2-
enone (2) as co-substrate would be economically unfavorable,
a cheaper hydrogen donor was sought. After attempts using 1-
indanone and hydroquinone failed, cyclohexane-1,4-dione
(5)dyielding 1,4-dihydroxybenzene (hydroquinone, 5a) as oxida-
tion productdwas found to provide a suitable alternative. Using
YqjM, all substrates showed enhanced conversion as compared to
b-methylcyclohex-2-enone (2) as co-substrate.
At this early stage, this novel NAD(P)H-independent cofactor
recycling system has not yet been fully optimized, particularly in
view of the (co)-substrate concentrations22 and the overall con-
versions. Incomplete conversions might be attributed to a certain
degree of enzyme inhibition, most presumably caused by the co-
product phenol(s), which are known to form charge-transfer
complexes with ﬂavins.23 Since the latter process is reversible, the
removal of phenols by in-situ (co)-product removal (ISPR)24 usingnot formed
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methylcyclohex-2-enone (2) catalyzed by enoate reductases.
CO 2Me
CO 2Me
(R)
4a4
3a3
O
O
CO 2Me
CO 2Me
O OH
2 2b
pH 7.5, 30 °C
NAD(P)H-free Tris-Buffer 
Enoate Reductase
5a5
OH
OH
O
O
H-Donor Systems
N-Ph
O
O
6a6
O
O
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(R)
Enzyme Substrate H-Donor Product Co-Product
c [%] e.e. [%] c [%]
OYE1 3 2 3a  2 n.d. 2b  5
OYE2 3 2 3a  1 n.d. 2b  3
YqjM 3 2 3a  17 >99 (R) 2b  21
OYE1 4 2 4a  4 n.d. 2b  6
OYE2 4 2 4a  3 n.d. 2b  4
YqjM 4 2 4a  22 76 (R) 2b  25
OYE1 3 5 3a  3 n.d. 5b  5
OYE2 3 5 3a  4 n.d. 5b  6
YqjM 3 5 3a  20 >99 (R) 5b  19
YqjM 4 5 4a  35 a 66 (R) 5b  29
YqjM 6 5 6a  51 b >99 (R) 5b  49
Scheme 3. Asymmetric bioreduction of activated alkenes via a coupled-substrate
approach. n.d.¼not determined. aA trace of 2,3-epoxy-2,6,6-trimethylcyclohexane-1,4-
dione was formed (3%), presumably due to spontaneous epoxidation of the C]C-
bond by H2O2 derived via enzyme-catalyzed reduction of O2.
21 bA trace of aniline was
detected as side product (3%).
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strategy has been successfully applied to industrial scale using
(ﬂavin-dependent) enzymatic Beyer–Villiger oxidation26 and (cy-
tochrome P450-dependent) alkene epoxidation mediated by whole
viable cells.273. Conclusion
An novel substrate-coupled C]C-bond bioreduction systemwas
developed, which depends only on a single ﬂavoprotein and neither
requires a second (dehydrogenase) recycling enzyme, nor a nico-
tinamide cofactor. Due to its simplicity, it has clear advantages over
other nicotinamide-independent alternative systems, such as light-
driven and electrochemical FAD-recycling systems.114. Experimental
4.1. General
GC–MS analyses were performed with an Agilent 7890A GC
system equipped with an Agilent 5975C mass-selective detector
(electron impact, 70 eV) using a (5%-phenyl)-methylpolysiloxane
phase column (Agilent HP-5 ms, 30 m, 250 mm, 0.25 mm). Helium
was used as carrier gas (column ﬂow: 2 mL/min). GC–FID analyses
were carried out with a Varian 3800 by using H2 as a carrier gas(14.5 psi). HPLC analyses were performed by using a Shimadzu
system equipped with a Chiralcel OD-H column (25 cm, 0.46 cm).
NMR spectra were measured on a Bruker AMX spectrometer at
360 MHz.
2-Methyl-2-cyclohexen-1-one (1), 2-methylcyclohexan-1-one
(1a), 3-methylcyclohexan-1-one (2a) and rac-levodione were pro-
vided by BASF (Ludwigshafen). Cyclohexanone, 2-cyclohexen-1-one,
phenol, 3-methyl-2-cyclohexen-1-one (2), 1,4-cyclohexanedione (5),
hydroquinone (5a), and N-phenyl-2-methylmaleimide (6) were
purchased from Aldrich. Citraconic acid was purchased from Alfa
Aesar and 4-ketoisophorone was from ABCR Co.
4.2. Synthesis of substrates and reference materials
4.2.1. rac-Methylsuccinic acid. Citraconic acid (105 mg, 0.81 mmol)
was dissolved in THF/EtOH 50:50 (10 mL) and was hydrogenated at
atmospheric pressure and room temperature in the presence of 10%
Pd/C (5 mg) as catalyst. After 24 h, the mixture was ﬁltered through
Celite and evaporated yielding 99% of rac-1b (106 mg, 0.80 mmol).
Mp¼110–115 C. 1H NMR (D2O): d 3.62–3.64 (d, 3H, J¼7.2 Hz), 4.96–
5.15 (m, 2H), 5.29–5.34 (m, 1H). 13C NMR (D2O): d 18.7, 38.2, 39.6,
179.0, 182.8.15
4.2.2. rac-Dimethyl-2-methylsuccinate (3a). A solution of rac-
methylsuccinic acid (32 mg, 0.24 mmol) in BF3/MeOH (0.5 mL, 14%)
was stirred at 100 C for 1 h. H2O (0.5 mL) was added and the re-
action mixture was extracted with n-hexane (31 mL). The com-
bined organic layers were dried over Na2SO4, ﬁltered and
evaporated, yielding 46% of rac-(3a) (17 mg, 0.11 mmol). 1H NMR
(CDCl3): d 1.22–1.24 (d, 3H, J¼7.2 Hz), 2.39–2.45 (dd, 1H, J¼6.06 Hz,
J¼16.52 Hz), 2.72–2.79 (dd, 1H, J¼8.15 Hz, J¼16.51 Hz), 2.91–2.94
(m, 1H), 3.69 (s, 3H), 3.71 (s, 3H). 13C NMR (CDCl3): d 17.0, 35.7, 37.4,
51.7, 51.9, 172.3, 175.7.15
4.2.3. Citraconic acid dimethylester (3). Substrate 3 was synthe-
sized according to the procedure described above starting from
citraconic acid. 1H NMR (CDCl3): d 2.06–2.07 (d, 3H, J¼1.6 Hz), 3.73
(s, 3H), 3.83 (s, 3H), 5.86–5.87 (d, 1H, J¼1.6 Hz). 13C NMR (CDCl3):
d 20.5, 51.8, 52.4, 120.6, 145.7, 165.4, 169.4.15
4.2.4. rac-N-Phenyl-2-methylsuccinimide (6a). N-Phenyl-2-methyl-
maleimide (6, 50 mg, 0.27 mmol) was dissolved in EtOAc (5 mL) and
was hydrogenated at atmospheric pressure at room temperature
using 10% Pd/C (2.8 mg) as catalyst. After 24 h, the mixture was ﬁl-
tered through Celite and evaporated yielding 94% of rac-6a (48 mg,
0.25 mmol). 1H NMR (CDCl3): d 1.47 (d, 3H, J¼7 Hz), 2.52 (dd, 1H,
J¼17.4 Hz, J¼4 Hz), 3.01–3.10 (m, 1H), 3.11 (dd, 1H, J¼17.3 Hz,
J¼9.2 Hz), 7.29–7.51 (m, 5H).15
4.3. General procedure for the screening for enzymatic
disproportionation of cyclohex-2-enone
An aliquot of the isolated enzyme OPR1, OPR3, YqjM, OYE1, OYE2,
OYE3, Z. mobilis ER, NEM-Red, MOR-Red, and PETN-Red (protein
purity>90%, protein content 90–110 mg/mL)was added to a Tris–HCl
buffer solution (0.8 mL, 50 mM, pH 7.5) containing cyclohex-2-
enone (10 mM). The mixture was shaken at 30 C and 120 rpm for
24 h and the products were extracted with EtOAc (20.5 mL). The
combined organic phases were dried (Na2SO4) and the resulting
samples were analyzed on achiral GC. Products were identiﬁed by
comparison with authentic reference materials via co-injection on
GC–MS and achiral GC. Column: 6% Cyanopropyl-phenyl phase
capillary column (Varian CP-1301, 30 m, 0.25 mm, 0.25 mm), detector
temperature 250 C, split ratio 30:1; temperature program: 80 C;
hold 2 min.; rise to 120 C with 5 C/min. TRet: cyclohex-2-enone
2.97 min, cyclohexanone 2.43 min, phenol 4.98 min.
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2-enone (2)
An aliquot of the isolated enzyme YqjM, OYE1, OYE2 (protein
purity>90%, protein content 90–110 mg/mL)was added to a Tris–HCl
buffer solution (0.8 mL, 50 mM, pH 7.5) containing the substrate 1
(10 mM) and the co-substrate 2 (10 mM). Themixture was shaken at
30 C and 120 rpm for 24 h and products were extracted with EtOAc
(20.5 mL). The combined organic phases were dried (Na2SO4) and
the resulting samples were analyzed on achiral GC. Products were
identiﬁed by comparison with authentic reference materials via co-
injection on GC–MS and achiral GC. Column: 14% cyanopropyl-
phenyl phase capillary column (J&W Scientiﬁc DB-1701, 30 m,
0.25 mm, 0.25 mm), detector temperature 250 C, split ratio 30:1.
Temperature program: 110 C, hold 5 min, rise to 200 C with 10 C/
min, hold 2 min. TRet: 2-methylcyclohexenone (1) 4.38 min; 2-
methylcyclohexanone (1a):3.70 min; 3-methylcyclohexenone (2)
6.27 min; 3-methylphenol (2b) 7.90 min; 2-methylphenol (1b)
7.02 min; 3-methylcyclohexanone (2a) 3.63 min.
4.5. Source of enzymes
The open reading frame of Lycopersicon esculentum OPR1 was
cloned into pET-21a and expressed as a C-terminal hexahistidine
tagged protein in E. coli BL21 cells. The expressed recombinant
protein was puriﬁed on a Ni-NTA afﬁnity column (Invitrogen)
according to the manufacturer’s protocol. L. esculentum OPR3 and
YqjM from Bacillus subtilis were expressed and puriﬁed as repor-
ted.14,28 OYE 1–3 from Saccharomyces sp. and NCR reductase from
Z. mobilis were provided by BASF (Ludwigshafen).15 PETNr from
Enterobacter cloacae, NemA from E. coli and MorR from Pseudomo-
nas putida M10 were provided by N.C. Bruce (Department of
Biology, University of York, York, UK).29
4.6. Cloning of estrogen-binding protein EBP1
Two synthetic genes encoding the Estrogen-Binding Protein
EBP1 from Candida albicans,3b the original sequence and one with
codon optimization for expression in E. coli, were sub-cloned into
the Multiple Cloning Site of a pDHE-1650 vector (BASF vector). The
pDHE-1650 vector as well as the synthetic genes were digested
with NdeI and HindIII (New England Biolabs) in the corresponding
buffer 2 (NEB) for 16 h at 37 C. After puriﬁcation of the digested
fragments from an agarose gel (GFX PCR, DNA, gel-band puriﬁca-
tion kit, GE Healthcare), the fragments were ligated with T4 DNA
ligase, provided by Roche. The resulting plasmids were transformed
in E. coli TG1.
4.7. Sequences of the synthetic genes
4.7.1. Original gene. atgactattgaatcaactaattcatttgttgtcccatcagatacta
aattaattgatgttactccattaggttcaacaaaattatttcaaccaattaaagtcggtaacaatg
ttttacctcaacgtattgcttatgtcccaaccaccagatttagagcttctaaagatcatattccaa
gtgatttacaattaaattattataatgctcgttctcaatatccaggtacattgattattactgaagc
aacatttgcatctgaaagaggtggtattgatttacatgttccaggtatttataatgacgctcaag
ctaaaagttggaagaaaatcaatgaagcaattcatggcaatggaagtttcagttcagttcaatt
atggtatttaggtagagttgctaatgctaaagatttgaaagattctggattacctcttattgcgcc
atcagcagtttattgggatgagaatagtgaaaaattggccaaagaagctggaaatgaattgag
agcattaactgaagaagaaattgatcatattgttgaagttgaatatcctaatgctgctaaacatg
cacttgaagcaggatttgattatgttgaaatccatggtgctcatggttacttgttggatcagtttt
taaatcttgcctctaataaaagaaccgataaatatggttgtggtagtattgaaaatcgtgcacg
attattattaagagtggttgataaattaattgaagttgttggtgctaatagattggcattacgttt
atcaccatgggctagtttccaaggtatggaaattgaaggtgaagaaatccattcatatattttac
aacaattacaacaacgtgctgataatggtcaacaattggcttatatttctcttgttgaacctcgtg
ttactggtatttatgatgtttctttaaaagatcaacaaggtcgtagtaatgaatttgcttataaga
tttggaaaggaaattttattcgtgctggtaattatacttatgatgctccagaatttaaaactttgattaatgatttaaagaatgatcgtagtattattggattttctagatttttcacttcaaatcctgattta
gtggaaaaattgaaattgggtaaaccattgaattattataatcgtgaagaattttataagtacta
caactatggttataattcttatgatgaatcagaaaagcaagtcattggtaaaccattggcatag
aagctt.
4.7.2. Synthetic gene. atgaccattgaaagcaccaacagctttgtggtgccgagcgat
accaaactgattgatgtgaccccgctgggcagcaccaaactgtttcagccgattaaagtgggc
aacaacgtgctgccgcagcgcattgcgtatgtgccgaccacccgctttcgcgcgagcaaagat
catattccgagcgatctgcagctgaactattataacgcgcgcagccagtatccgggcaccctg
attattaccgaagcgacctttgcgagcgaacgcggcggcattgatctgcatgtgccgggcattt
ataacgatgcgcaggcgaaaagctggaaaaaaattaacgaagcgattcatggcaacggcag
ctttagcagcgtgcagctgtggtatctgggccgcgtggcgaacgcgaaagatctgaaagata
gcggcctgccgctgattgcgccgagcgcggtgtattgggatgaaaacagcgaaaaactggcg
aaagaagcgggcaacgaactgcgcgcgctgaccgaagaagaaattgatcatattgtggaag
tggaatatccgaacgcggcgaaacatgcgctggaagcgggctttgattatgtggaaattcatg
gcgcgcatggctatctgctggatcagtttctgaacctggcgagcaacaaacgcaccgataaat
atggctgcggcagcattgaaaaccgcgcgcgcctgctgctgcgcgtggtggataaactgattg
aagtggtgggcgcgaaccgcctggcgctgcgcctgagcccgtgggcgagctttcagggcatg
gaaattgaaggcgaagaaattcatagctatattctgcagcagctgcagcagcgcgcggataa
cggccagcagctggcgtatattagcctggtggaaccgcgcgtgaccggcatttatgatgtgag
cctgaaagatcagcagggccgcagcaacgaatttgcgtataaaatttggaaaggcaactttat
tcgcgcgggcaactatacctatgatgcgccggaatttaaaaccctgattaacgatctgaaaaa
cgatcgcagcattattggctttagccgcttttttaccagcaacccggatctggtggaaaaactg
aaactgggcaaaccgctgaactattataaccgcgaagaattttataaatattataactatggct
ataacagctatgatgaaagcgaaaaacaggtgattggcaaaccgctggcgtagctaagctt.4.8. Expression of estrogen-binding protein EBP1
The enzymes were expressed in E. coli TG1 (Stratagene). LB
medium (2 ml) with antibiotic supplement (100 mg/mL ampicillin)
were inoculated with a single colony of E. coli TG1 pDHE-EBP1 and
incubated with shaking (220 rpm) for 5 h at 37 C. This culture was
diluted 1:100 with fresh LB medium (100 mg/mL, 2 g/L rhamnose,
the pDHE vector has a rhamnose-inducible promoter) and in-
cubated with shaking (220 rpm) for 16 h at 37 C. Then the cells
were harvested by centrifugation (5 min, 10,000 rpm) and washed
with 50 mM Tris–HCl pH 7.5. The cell pellet was used for further
experiments.4.9. General procedure for the bioreduction of activated
alkenes 3, 4, and 6 using 3-methyl-2-cyclohexen-1-one (2) or
1,4-cyclohexanedione (5) as H-donor
An aliquot of isolated enzyme OYE1, OYE2, and YqjM (protein
purity >90%, protein content 90–110 mg/mL) was added to a Tris–
HCl buffer solution (0.8 mL, 50 mM, pH 7.5) containing substrate (3,
4, or 6, 10 mM) and 3-methyl-2-cyclohexen-1-one (2) or 1,4,-
cyclohexanedione (5) (10 mM). The mixture was shaken at 30 C
and 120 rpm for 24 h and the products were extracted with EtOAc
(20.5 mL). The combined organic phases were dried (Na2SO4) and
the resulting samples were analyzed on achiral GC–MS and achiral
GC. Column: 14% cyanopropyl-phenyl phase capillary column, J&W
Scientiﬁc DB-1701, 30 m, 0.25 mm, 0.25 mm, detector temperature
250 C, split ratio 30:1. Temperature program: 110 C, hold 5 min,
rise to 200 C with 10 C/min, hold 4 min. TRet: 3-Methylcyclo-
hexenone (2) 6.27 min; 3-methylcyclohexanone (2a) 3.63 min;
citraconic acid dimethylester (3) 6.91 min; dimethyl-2-methyl-
succinate (3a) 5.89 min; 4-ketoisophorone (4) 8.22 min; levodion
(4a) 9.26 min; 1,4,-cyclohexanedione (5) 8.38 min; hydroquinone
(5a) 13.51 min; N-phenyl-2-methylmaleimide (6) 15.84 min;
N-phenyl-2-methylsuccinimide (6a) 14.12 min;
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conﬁguration
The enantiomeric excess of 1a and 3a was determined using
a modiﬁed b-cyclodextrin capillary column (Chiraldex B-TA, 40 m,
0.25 mm). Detector temperature 200 C, injector temperature
180 C, split ratio 25:1. Temperature program for 1a: 80 C hold
2 min, 5 C/min to 105 C, 10 C/min, hold 4 min. Retention times:
(R)-1a 6.34 and (S)-1a 6.47 min. Temperature program for 3a: 90 C
hold 4 min, 3 C/min to 115 C, 30 C/min to 180 C. Retention
times: (S)-3b 7.33 min; (R)-3b 7.45 min; The enantiomeric excess of
4a was determined using a b-cyclodextrin capillary column (CP-
Chirasil-DEX CB, 25 m, 0.32 mm, 0.25 mm ﬁlm). Temperature pro-
gram for 4a: 90 C hold 2 min, 4 C/min to 115 C, 20 C/min to
180 C, hold 2 min. Retention times: (R)-4a 6.42; (S)-4a 6.74 min.
The enantiomeric excess of 8b was determined on HPLC using
n-heptane/i-PrOH 95:5 (isocratic) at 18 C and 1 mL/min. Retention
times: (R)-8b 25.10 min; (S)-8b 29.15 min.15
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